414869-76-4

Upstream product

• 414869-73-1 (E)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)-2-pentenoic acid cyclohexylammonium salt 
• 108-91-8 cyclohexylamine 
• 565-80-0 2,4-dimethylpentan-3-one 
• 5002-26-6 3-methyl-4-phenylbromobenzene 
• 98-80-6 phenylboronic acid 
• 116632-39-4 2-methyl-4-bromoiodobenzene 
• 348622-94-6 3-(diethoxyphosphoryl)succinic acid 1-tert-butyl ester 
• 77924-28-8 4-tert-butyl 1-ethyl 2-(diethoxyphosphoryl)succinate 

Downstream Products

• 230962-37-5 (R)-2-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methyl-1,1'-biphenyl-4-yl)-pentanoic acid 
• 230961-86-1 tert-butyl (3R)-3-({[(1S)-2,2-dimethyl-1-({[(1S)-2-methoxy-1-phenylethyl]amino}carbonyl)propyl]amino}carbonyl)-6-(3-methyl-4-phenylphenyl)hexanoate 
• 230961-21-4 UK-370106 

Relevant academic research and scientific papers

Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif

An efficient and practical synthesis is presented of the pharmaceutically active MMP-3 inhibitor UK-370,106 (1) via an olefination/catalytic asymmetric hydrogenation sequence. Commercially available 5-bromo-2-iodotoluene was converted in two steps to the

Novel olefination process to itaconate and succinate derivatives

An efficient and selective process, capable of scale-up, to make itaconate derivatives of formula (IV), and/or succinate derivatives of formula (V) and/or (VI) by asymmetric hydrogenation of the itaconate derivatives.